Antifibrinolytic therapy in the acute period following aneurysmal subarachnoid hemorrhage. Preliminary observations from the Cooperative Aneurysm Study.
Antifibrinolytic therapy remains a controversial issue in the management of subarachnoid hemorrhage (SAH). The relationship of antifibrinolytic therapy with mortality, rebleeding, ischemia, hydrocephalus, and clotting abnormalities was studied in 672 patients in the International Cooperative Study on the Timing of Aneurysm Surgery. The patients with antifibrinolytic therapy had a significantly lower rebleeding rate, but higher rates of ischemic deficits and hydrocephalus. The net result was no difference in mortality in the 1st month following the initial SAH. Further clinical trials are needed to determine the overall effects of antifibrinolytic therapy.
D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002543:Cerebral Hemorrhage / Q000517:prevention & control; D005260:Female; D006801:Humans; D006849:Hydrocephalus / Q000139:chemically induced; D002532:Intracranial Aneurysm / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D002546:Ischemic Attack, Transient / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D012422:Rupture, Spontaneous; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D013997:Time Factors
D000933:Antifibrinolytic Agents